MiR-149 controls non-alcoholic fatty liver disease by targeting FGF-21 [40]; it also inhibits the ATF6 pathway to reduce inflammation and apoptosis in nonalcoholic fatty liver disease brought on by endoplasmic reticulum stress [41]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.